Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that mainly affects the axial skeleton including the spine and the sacroiliac joints. ECM remodelling occurring in the affected tissues, can be quantified by tissue-specific biomarkers. This enables the monitoring of disease activity, providing valuable insights into the disease mechanisms and complexity in axSpA.

Psoriatic arthritis (PsA) is a systemic inflammatory disease affecting both skin and musculoskeletal tissues, including bone, synovium, and cartilage. Present in up to 30% of psoriasis patients, PsA is marked by extensive tissue remodeling and immune activation. Nordic Bioscience’s ProteinFingerPrint Technology™ delivers ECM-derived, tissue-specific biomarkers that quantify structural damage and immune cell activity. These biomarkers enable differentiation between psoriasis and PsA, support early diagnosis, guide treatment selection, and monitor therapeutic response. Their specificity and mechanistic relevance offer critical advantages over broad-spectrum omics approaches in advancing precision medicine for psoriatic disease.

Systemic skin diseases with local manifestations are characterized by excessive tissue remodeling and immune cell activity. Tissue-specific biomarkers, quantifying and monitoring immune cell activity, are key advantages when we want to understand the disease mechanisms and complexity in systemic sclerosis and lead to targeted successful treatments. On this page, we explain how our biomarkers for systemic sclerosis can provide such crucial value.

RheumaTrace™ is a next-generation biomarker panel developed to advance precision medicine in rheumatology. Built on over 30 years of research and more than 200 publications, it features seven biomarkers that capture key aspects of connective tissue degradation and immune activity. RheumaTrace™ enables drug developers to track disease activity, predict treatment response, and identify target patient populations—supporting smarter, faster decisions in clinical development.